Copyright
©The Author(s) 2018.
World J Gastrointest Oncol. Oct 15, 2018; 10(10): 336-343
Published online Oct 15, 2018. doi: 10.4251/wjgo.v10.i10.336
Published online Oct 15, 2018. doi: 10.4251/wjgo.v10.i10.336
Table 2 The use of biomarkers with expanded morphological criteria
| Ref. | Year | No. of patients | Criteria | Overall survival | |
| Within criteria | Beyond criteria | ||||
| Kyoto[21] | 2007 | 136 | Up to 10 tumors, all ≤ 5 cm; DCP ≤ 400 ng/mL | 87% (5-yr) | 37% (5-yr) |
| Kyushu[22] | 2007 | 40 | Any number, tumor diameter ≤ 5 cm; DCP < 300 ng/mL | 77% (3-yr) | 40% (3-yr) |
| Seoul[23] | 2007 | 140 | Any number, tumor diameter ≤ 5 cm; AFP ≤ 400 ng/mL | 87% (5-yr) | 23% (5-yr) |
| Hangzhou[24] | 2008 | 195 | Total tumor diameter ≤ 8 cm; or total tumor diameter > 8 cm and grade I/II and AFP ≤ 400 ng/mL | 71% (5-yr) | 19% (5-yr) |
- Citation: Yaprak O, Acar S, Ertugrul G, Dayangac M. Role of pre-transplant 18F-FDG PET/CT in predicting hepatocellular carcinoma recurrence after liver transplantation. World J Gastrointest Oncol 2018; 10(10): 336-343
- URL: https://www.wjgnet.com/1948-5204/full/v10/i10/336.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v10.i10.336